Skip to main content

Waltham cancer biotech goes public in $118M IPO

Xilio Therapeutics, the Waltham-based cancer biotech that rebranded from Akrevia Therapeutics back in early 2020, has made its Wall Street debut. The company raised $117.5 million in an IPO on Friday, selling nearly 7.4 million shares at $16 apiece.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.